Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $86.00 at Nomura

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Nomura to $86.00 in a report published on Friday, February 9th. They currently have a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on the company. BMO Capital Markets reduced their price target on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating on the stock in a research report on Friday, February 9th. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating on the stock in a research note on Friday, February 9th. B. Riley began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 price objective for the company. Piper Jaffray Companies reissued a buy rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Finally, Needham & Company LLC reaffirmed a buy rating and set a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $126.76.

Alnylam Pharmaceuticals (ALNY) opened at $122.88 on Friday. The firm has a market capitalization of $12,271.76, a price-to-earnings ratio of -22.71 and a beta of 2.69. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a fifty-two week low of $45.00 and a fifty-two week high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. Alnylam Pharmaceuticals’s quarterly revenue was up 116.6% on a year-over-year basis. During the same period last year, the firm posted ($1.32) EPS. equities research analysts anticipate that Alnylam Pharmaceuticals will post -6.81 earnings per share for the current fiscal year.

In related news, CEO John Maraganore sold 73,415 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at approximately $29,207,062.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 146,409 shares of company stock worth $19,279,377. Insiders own 4.30% of the company’s stock.

A number of institutional investors have recently modified their holdings of ALNY. Prudential Financial Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 200 shares during the last quarter. Northern Trust Corp raised its position in Alnylam Pharmaceuticals by 5.0% in the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock worth $30,072,000 after purchasing an additional 17,862 shares during the period. Suntrust Banks Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $320,000. Parametric Portfolio Associates LLC increased its position in shares of Alnylam Pharmaceuticals by 8.2% during the second quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock worth $5,180,000 after acquiring an additional 4,913 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 59.1% during the second quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock worth $14,311,000 after acquiring an additional 66,651 shares during the period. 88.61% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $86.00 at Nomura” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/19/nomura-boosts-alnylam-pharmaceuticals-alny-price-target-to-86-00-updated.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply